SHR-1314

Phase 3Small molecule

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1314 is one of 146 small molecule programs targeting Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

145

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Lupus NephritisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

ArthritisPhase 3

Active, not recruiting

PsoriasisPhase 1/Phase 2

Active, not recruiting

Psoriatic ArthritisPhase 3

Active, not recruiting

Lupus NephritisPhase 2

Active, not recruiting

Ankylosing SpondylitisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Not yet recruiting

Psoriasis

NCT06833307

Q4 2028

Phase 3Recruiting

Arthritis

NCT06860750

Clinical

Trials by Indication[1]

Psoriasis4 trials

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04839016·660 enrolled

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Not yet recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06833307·90 enrolled

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT03463187·211 enrolled

Show 1 more trial

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03710681·16 enrolled

MPA2 trials

A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04527484·130 enrolled

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04326881·30 enrolled

Psoriatic Arthritis2 trials

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Completed· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT05055934·112 enrolled

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06640257·200 enrolled

AxSpA1 trial

Safety, Tolerability and PK of SHR1314 in axSpA

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03704428·45 enrolled

Ankylosing Spondylitis1 trial

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Completed· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2/3·NCT04840485·548 enrolled

5 more indications

Lupus Nephritis1 trial

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

Unknown status· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT04924296·60 enrolled

Tics1 trial

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Completed· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT06182384·46 enrolled

Arthritis1 trial

A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06860750·380 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Terminated· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT05394857·7 enrolled

Unspecified1 trial

A Study of SHR-1314 in Healthy Subjects

Completed·AAtridia Pty Ltd.·Phase 1·NCT02934412·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for SHR-1314. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1314 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1314. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1314

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2028

Trials by Indication[1]

Psoriasis4 trials

MPA2 trials

Psoriatic Arthritis2 trials

AxSpA1 trial

Ankylosing Spondylitis1 trial

Lupus Nephritis1 trial

Tics1 trial

Arthritis1 trial

Efficacy and Safety1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News